tbuckley/cabot-search huggingface dataset:
Loss and Gain of MeCP2 Cause Similar Hippocampal Circuit Dysfunction that Is Rescued by Deep Brain Stimulation in a Rett Syndrome Mouse Model
Authors: Hui Lu, Ryan T. Ash, Lingjie He, Sara E. Kee, Wei Wang, Dinghui Yu, Shuang Hao, Xiangling Meng, Kerstin Ure, Aya Ito-Ishida, Bin Tang, Yaling Sun, Daoyun Ji, Jianrong Tang, Benjamin R. Arenkiel, Stelios M. Smirnakis, Huda Y. Zoghbi
Journal: Neuron (2016)
Efficacy and safety of tribendimidine against Opisthorchis viverrini : two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials
Authors: Somphou Sayasone, Peter Odermatt, Youthanavanh Vonghachack, Syda Xayavong, Kanpaseuth Senggnam, Urs Duthaler, Kongsap Akkhavong, Jan Hattendorf, Jennifer Keiser
Journal: The Lancet Infectious Diseases (2016)
LGL Disorders: From An Inflammatory-Mediated To a Self-Maintaining Proliferation
Authors: Antonella Teramo, Cristina Gattazzo, Francesca Passeri, Gregorio Barilà, Enrica Bovo, Chiara Nardin, Alberto Campagnaro, Anna Cabrelle, Veronica Martini, Elisa Boscaro, Antonio Branca, Monica Facco, Livio Trentin, Gianpietro Semenzato, Renato Zambello
Journal: Blood (2013)
Long-Term Exposure to Traffic-Related Air Pollution and Risk of Incident Atrial Fibrillation: A Cohort Study
Authors: Maria Monrad, Ahmad Sajadieh, Jeppe Schultz Christensen, Matthias Ketzel, Ole Raaschou-Nielsen, Anne Tjønneland, Kim Overvad, Steffen Loft, Mette Sørensen
Journal: Environmental Health Perspectives (2016)

Atrial fibrillation is the most common sustained arrhythmia and is associated with cardiovascular morbidity and mortality. The few studies conducted on short-term effects of air pollution on episodes of atrial fibrillation indicate a positive association, though not consistently.
Abstract 4009: Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep-sequencing
Authors: Elke Nolte, Martin Hart, Sven Wach, Jaroslaw Szczyrba, Helge Taubert, Tilman Rau, Arndt Hartmann, Friedrich A. Grässer, Bernd Wullich
Journal: Cancer Research (2015)

Abstract Background: MicroRNAs (miRNAs) are short, non-coding RNAs that post-transcriptionally regulate gene expression and play an important role in tumorigenesis. Previous deep-sequencing identified the microRNA profile of prostate carcinoma (PCa) vs. non-malignant prostate tissue. As an extension of our recent analyses, we now compared organ-confined prostate tumors (pT2), tumors with extra capsular growth (pT3, pN0), and lymph node metastasizing (pN1) PCa relative to corresponding non-malignant prostate tissue and healthy prostate tissue. Material and Methods: We performed comparative miRNA expression profiling using deep sequencing of cDNA libraries. Potential target genes of deregulated miRNAs were identified by database analysis and subsequently validated in vitro using reporter gene constructs. miRNA and mRNA expression was determined using quantitative real-time PCR. Results: The miRNA expression from the healthy and non-malignant tissue is consistent with our previous findings, indicating a high fidelity of the method employed. Some miRNAs (miR-375, miR-148a, miR-141 and miR-21) are expressed at increasing levels with increasing tumor stage, while other miRNAs (miR-200b/c, miR-25, miR-17 or miR-93) are up-regulated only from organ-confined tumors (pT2) to tumors with extra-capsular growth (pT3) but then expressed at lower levels after the transition to lymph node metastasizing tumors (pN0 vs. pN1). The same trend was seen in qRT-PCR analysis but due to the limited sample number, no significance was reached. Interestingly, miR-375, found to be up-regulated in tumor vs. normal tissue, and miR-15a, found induced by sequencing in T2 and T3 tumors but not in lymph node metastasizing tumors, target the phosphatases PHLPP1 and PHLPP2, respectively. PHLPP1 and PHLPP2 dephosphorylate members of the AKT-family of signal transducers thereby inhibiting cell growth. Co-expression of miR-15a and miR-375 resulted in down-regulation of PHLPP1/2 and a strongly increased PCa cell growth. Conclusion: miRNA profiling of pT2 (pN0), pT3 (pN0), and lymph node metastasizing prostate carcinoma (pN1) by deep sequencing revealed clearly changed miRNA levels. Citation Format: Elke Nolte, Martin Hart, Sven Wach, Jaroslaw Szczyrba, Helge Taubert, Tilman Rau, Arndt Hartmann, Friedrich A. Grässer, Bernd Wullich. Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep-sequencing. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4009. doi:10.1158/1538-7445.AM2015-4009
The Oncogenic Mir-17-92 MicroRNA Cluster Is Inhibited by EGR2 During Macrophage Differentiation Via JARID1b-Mediated Histone 3 Lysine 4 Demethylation
Authors: Vit Pospisil, Karin Vargova, Juraj Kokavec, Jana Rybarova, Filipp Savvulidi, Emanuel Necas, Peter Laslo, Jiri Zavadil, Tomas Stopka
Journal: Blood (2010)
Abstract 3476: Factors related to cervical cancer screening differences between regions around Bagamoyo, Tanzania
Authors: Brianna Rooney, Autumn Cummings, Amr Soliman, Crispin Kahesa
Journal: Cancer Research (2016)

Abstract Background: With cervical cancer being among the most common cancers in East Africa among women, it is important to look at the factors related to referral differences in Tanzania, especially in rural areas where there is little to no access to cervical cancer screening clinics (CCS). Cervical cancer is related to HIV because a woman is 13.3 times more likely to develop cervical abnormalities if she is HIV positive. There are more HIV-positive women that attend CCS than HIV-negative women. This leads to more research to discover the variation in screening rates between HIV-positive and HIV-negative patients within the same village, as well as the variation in the screening rates between different villages. Purpose: This study aims to determine the multi-level factors related to differences in cervical cancer screening frequencies between villages in Bagamoyo, Tanzania, and providers’ perception of barriers to screening at the Bagamoyo District Hospital (BDH). Factors identified that influence CCS attendance are HIV prevalence, distance to BDH, number of clinics, and female population. Methods/Design: This mixed method design includes data obtained from the Tanzania Ministry of Health, the Bagamoyo District Medical Officer, and BDH medical records, as well as additional data from questionnaires conducted with health care providers, doctors or nurses, employed at BDH. The questionnaires included written informed consent. Data obtained from CCS medical records were used to estimate the frequency of women screened from 42 villages. ANOVA analysis was used to compare the percent of women screened from each village to the identified risk factors, HIV prevalence, distance, access to clinics, and population. Chi-square analysis was conducted in order to determine associations between type of health care provider and previously identified barriers to screening. Discussion: This is the first study to examine providers’ perceived barriers to screening in relation to previously identified factors related to differences in cervical cancer screening rates. Further analysis of patient perceived barriers to screening should be conducted in order to better understand differences in screening rates. Funding: Funding was received from the National Cancer Institute through the Cancer Epidemiology Education in Special Populations program. Citation Format: Brianna Rooney, Autumn Cummings, Amr Soliman, Crispin Kahesa. Factors related to cervical cancer screening differences between regions around Bagamoyo, Tanzania. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3476.
Abstract 1610: Inhibiting HuR, a RNA-binding protein, for inhibition of pancreatic cancer EMT and CSCs
Authors: Ruochen Dong, Kishore Polireddy, Ying Zhang, Qi Chen
Journal: Cancer Research (2016)

Abstract Purpose Epithelial- mesenchymal transition (EMT) contributes importantly to cancer cell metastasis, and formation of cancer stem cells (CSCs). An RNA-binding protein, HuR, plays an important role in many solid tumors for promoting cell proliferation, metastasis, anti-apoptosis and drug resistance. However, the role of HuR in cancer cell EMT and CSC has not been elucidated. Here we aim to investigate the role of HuR in pancreatic cancer EMT and CSC, and developing a new HuR inhibitor ST-3 as an inhibitor for pancreatic cancer EMT and CSCs. Methods Fluorescence Polarization assay and surface plasmon resonance assay was utilized for St-3, HuR and target mRNA binding. Scratching assay and matrigel invasion assay were used for cell migration and invasion, whereas MTT assay for viability. Tumor spheroid formation assay was used as an indication of CSCs. Western blot and RT-qPCR was used for protein and mRNA expression. Results Knockdown of HuR with siRNA inhibited migration of pancreatic cancer cells MIAPaCa-2, and suppressed the expression of Vimentin, Snail, and increased E-cadherin expression, showing inhibition in EMT. The suppression of Snail is due to accelerated mRNA decay. Overexpression of HuR protected mRNA of Snail from degradation, suggesting that Snail is a direct target of HuR. Knockdown of HuR also decreased pancreatic cancer spheroids formation. St-3 inhibited the proliferation of pancreatic cancer cell lines more potently in HuR-high cells MIAPaCa-2 (IC50 ∼2 μM), than in HuR-low cells BxPc-3 and PANC-1 (IC50 6-20 μM). St-3 directly bound to HuR, and inhibited binding of HuR with its target mRNAs. St-3 treatment mimicked the HuR knockdown effects in inhibiting cell migration, EMT, and spheroids formation. Conclusion HuR is an important regulator in pancreatic cancer EMT and CSCs. ST-3 as a novel HuR inhibitor inhibited pancreatic cancer EMT and CSCs. Further investigation is under way. Citation Format: Ruochen Dong, Kishore Polireddy, Ying Zhang, Qi Chen. Inhibiting HuR, a RNA-binding protein, for inhibition of pancreatic cancer EMT and CSCs. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1610.
Handbook for Prescribing Medications during Pregnancy.
Journal: Annals of Internal Medicine (1988)

handbook for prescribing medications during pregnancy is available in our book collection an online access to it is set as public so you can download it instantly. Our digital library spans in multiple locations, allowing you to get the most less latency time to download any of our books like this one. Kindly say, the handbook for prescribing medications during pregnancy is universally compatible with any devices to read.
Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R
Authors: Kieron Dunleavy, Ariela Noy, Jeremy S. Abramson, Ann S. LaCasce, Brian K Link, Samir Parekh, Deepa Jagadeesh, Philip J Bierman, Ronald T. Mitsuyasu, Ramakrishna Battini, Peter R Watson, David Peace, Bruce J Averbrook, Harris V. Naina, Joseph W Leach, Wahid T Hanna, Bayard L. Powell, Sunil Nagpal, Mark Roschewski, Andrea N Lucas, Seth M. Steinberg, Brad S Kahl, Jonathan W. Friedberg, Richard F Little, Nancy L Bartlett, Michelle A. Fanale, Wyndham H Wilson
Journal: Blood (2015)
Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
Authors: Howard I. Scher, Jessica Louw, Adam Jendrisak, Richard Martin Bambury, Daniel Costin Danila, Dana E. Rathkopf, Zaina Arslan, Nicole A. Schreiber, David Lu, Rachel Krupa, Dena Marrinucci, Mark Landers, Ryan Vance Dittamore
Journal: Journal of Clinical Oncology (2015)

147 Background: The optimal sequence to administer approved life prolonging ARS inhibitors: Abiraterone (A) and Enzalutamide (E),and taxanes: Docetaxel (D) and Cabazitaxel (C), to maximize individual pt benefit is an unmet medical need. Sensitivity to an individual agent is dependent on the intrinsic biology of the tumor and the treatment to which it has been exposed. For each agent, response rates are lower in pts who have received prior treatment with any of the other drugs, but for the individual, sensitivity to one does not necessarily predict sensitivity to the other. We sought to develop response and resistance signatures to A &amp; E or D &amp; C from a baseline blood sample. Methods: 91 pt blood samples collected from 79 pts for CTC analysis with the Epic Sciences platform prior to treatment (27 pre-A, 28 pre-E, 28 pre-D, 8 pre-C). Epic analysis identified traditional CTCs (CK+, CD45-, intact nuclei, morph distinct), CK- CTCs (CK-, CD45-, intact nuclei, morph distinct), small CTCs (CK+, CD45-, intact nuclei, small cell size), and CTC clusters. IF staining for AR N, AR C exp were performed, digital pathology algorithms analyzed CTC morphology. A classifier was developed to associate clinical phenotypes with outcome to a specific agent. Results: A and E signatures included: AR N/C exp. and presence of CK+, AR+, Nucleoli+ CTCs. D and C signatures by: presence of CK+, small, AR-, Nucleoli+ CTCs. Multivariate algorithms for A and E and D &amp; C were statistically associated with de novo resistance. Line of therapy was not a univariate predictor of response. Conclusions: Characterization of CTCs identified predictive biomarkers of sensitivity to ARS Tx and taxane chemotherapy in mCRPC pts. The proposed A&amp;E signature differs from C and D, providing the opportunity to better guide treatment selection and improve patient outcomes using a real-time, non-invasive blood biopsy. Prospective trials to validate results are planned. [Table: see text]
Ectopic Expression and Role of RCAN1 in Myeloid Leukemia Cells.
Authors: Shin-ichiro Fujiwara, Tadashi Nagai, Satoru Kikuchi, Mitsuyo Uesawa, Chihiro Sakurai, Ken Ohmine, Jiro Kikuchi, Yusuke Furukawa, Keiya Ozawa
Journal: Blood (2009)
Different Approaches Of Allogeneic Stem Cell Transplantation For Acute Leukemias In Suzhou (China) Lead To Similar Outcome Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis
Authors: Jia Chen, Yin Lu, Myriam Labopin, Depei Wu, Mohamad Mohty, Norbert C. Gorin
Journal: Blood (2013)
Abstract 2717: Reintroduction of DAXX suppresses alternative lengthening of telomeres in osteosarcoma
Authors: Kathryn E. Driest, Joshua J. Waterfall, Robert L. Walker, Marbin A. Pineda, Ogan Abaan, Yuelin J. Zhu, Yonghong Wang, Corbin D. Ester, Sean R. Davis, Sven Bilke, Paul S. Meltzer
Journal: Cancer Research (2016)

Abstract The unlimited proliferative capacity of cancer cells is closely linked to maintenance of their telomeres, which shorten with each cell division in normal cells. Cancer cells are able to maintain telomere length by multiple mechanisms, including activation of telomerase and the recombination based alternative lengthening of telomeres (ALT) pathway. ALT is prevalent in osteosarcoma, with approximately 50% of osteosarcoma cases using ALT for telomere maintenance. Mutations in the ATRX/DAXX chromatin remodeling complex and histone H3.3 correlate with activation of the ALT pathway in several tumor systems. While loss of ATRX is a frequent event in osteosarcoma tumors, alterations of DAXX have not been reported. We characterized the telomere maintenance mechanisms utilized by 11 osteosarcoma cell lines. Of these, 45% (5/11) were ALT positive and 45% (5/11) were telomerase positive. One cell line possessed features of both telomere maintenance mechanisms. Among ALT positive osteosarcoma cell lines, we observed frequent loss of ATRX expression (4/5) and a previously unreported translocation resulting in disruption of DAXX. The translocation abolishes recruitment of DAXX to nuclear PML bodies and prevents normal DAXX function. By reintroducing full length DAXX, we were able to suppress telomere maintenance by ALT as evidenced by multiple assays including loss of C-circles and ALT-associated PML bodies, thus demonstrating that continued DAXX deficiency is necessary for maintenance of the ALT mechanism. Suppression of ALT by DAXX reintroduction did not result in compensatory activation of telomerase. This first demonstration of ALT suppression by DAXX supports a mechanistic connection between loss of the ATRX/DAXX chromatin remodeling complex and telomere maintenance by ALT. Understanding this relationship may uncover vulnerabilities specific to ALT tumors that could potentially lead to the development of targeted therapies for diverse cancers that depend on the ALT pathway. Citation Format: Kathryn E. Driest, Joshua J. Waterfall, Robert L. Walker, Marbin A. Pineda, Ogan Abaan, Yuelin J. Zhu, Yonghong Wang, Corbin D. Ester, Sean R. Davis, Sven Bilke, Paul S. Meltzer. Reintroduction of DAXX suppresses alternative lengthening of telomeres in osteosarcoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2717.
PTU-054 Faecal calprotectin in patients with suspected small bowel crohn’s disease: correlation with small bowel capsule endoscopy: Abstract PTU-054 Table 1
Authors: MF Hale, K Drew, ME McAlindon, AJ Lobo, R Sidhu
Journal: Gut (2015)

Introduction  Faecal calprotectin (FC) is a stool biomarker recommended as a simple, non-invasive test to distinguish between inflammatory bowel disease (IBD) and functional bowel disorders. Despite a good correlation with colonic inflammation, FC is felt to be less accurate at identifying small bowel (SB) inflammation. Small bowel capsule endoscopy (SBCE) has a high sensitivity for detecting SB mucosal inflammation. We investigated the correlation between FC and SBCE in patients with suspected IBD.  Method  We prospectively correlated the findings of SBCE with FC levels in patients under investigation for suspected IBD. Patient demographics, clinical symptoms, medications and blood parameters: haemoglobin (Hb), albumin, ESR and CRP were collected. SBCE findings including Lewis scores were analysed against FC values and final diagnosis.  Results  127 patients were included, mean age 42 years (range 18–75 years), 85 female. Presenting symptoms included: a combination of diarrhoea, abdominal pain and bloating (74%), diarrhoea alone (13%), abdominal pain alone (12%), rectal bleeding (1%). Median time from FC measurement to SBCE was 62 days. 12% had a family history of IBD, 14% were current smokers. 6 patients with a diagnosis of colonic pathology were excluded.  Results are presented in Table 1. Of the 61 patients with FC >100 µg/g, 14 (23.0%) had clinically significant SB findings (12 SB ulcers, 2 villous atrophy) and mean FC levels 468 µg/g (range 112–1010 µg/g). Overall a definitive diagnosis was made in 10 patients (9 Crohn’s disease, 1 NSAID enteropathy), the remaining 10 patients are undergoing further evaluation. FC >50 µg/g was significantly associated with clinically relevant SBCE findings (χ² p = 0.02). FC had a sensitivity 81%, specificity 40%, positive predictive value 42% and negative predictive value (NPV) 80%. Receiver operating curve analysis showed an area under the curve (AUC) of 0.626 for FC, similar to CRP (AUC 0.638) but better than ESR (AUC 0.524) and Hb (AUC 0.545). Albumin most closely correlated with an AUC 0.686. Multiple logistical regression showed serum albumin to be the only variable significantly associated with positive SBCE (p = 0.032). Lewis score significantly correlated with FC value (r = 0.793, p   Conclusion  With a reasonable sensitivity and NPV, FC could be most effectively utilised to screen out patients where further SB investigation is unnecessary. However, in our series 1 patient with FC ≤50 µg/g had SB Crohn’s disease. Thus at best, FC can be only be recommended as an adjunct to clinical decision making, when patient factors and other biochemical parameters are also taken into account.  Disclosure of interest  None Declared.
Abstract 3005: The impact of mitochondrially targeted oncology agents on mitochondrial DNA (mtDNA) integrity
Authors: Kaytee L. Pokrzywinski, Thomas G. Biel, Dmitry Kryndushkin, V. Ashutosh Rao.
Journal: Cancer Research (2016)

Abstract Reactive oxygen species (ROS) are natural byproducts of mitochondrial oxidative phosphorylation. Dysfunction in electron shuttling leads to enhanced ROS production that is notorious for inflicting damage to macromolecules. Mitochondrial DNA (mtDNA) is particularly sensitive to ROS as it is located in close proximity to the respiratory chain. Additionally, mtDNA lack histones which are known to provide protection from ROS. Mitochondria also have limited DNA repair mechanisms making damage to mtDNA more detrimental to mitochondrial physiology. Recent evidence suggests that oxidative insult, leads to mtDNA degradation to prevent the accumulation of mutagenic base lesions, which is enabled by the high redundancy of mtDNA. The primary objectives of this study were to determine the impact of redox-active mitochondrial-targeted chemotherapeutic agents on mitochondrial physiology and mtDNA integrity. All experiments were performed in two cancer cell lines [MDA-MB-231 (breast) and H23 (lung)] that were treated with 2 uM of the mitochondrial-targeted redox-active compounds: MitoTempol [C4 (MT4)], MitoQuinone (MQ) and MitoChromanol-Acetate (MCA) for 1 or 24 hrs. Mitochondrial status was determined by measuring mitochondrial membrane potential, superoxide production, oxygen consumption rate (OCR) and protein levels of the respiratory chain complexes using the JC-1 and MitoSOX assays, Seahorse XF analysis, and immunoblotting, respectively. Next, mtDNA integrity was analyzed by quantifying the degree of mtDNA fragmentation using PCR amplification of a 10kb fragment compared to a short 100bp fragment. Moreover, changes in the mtDNA replication machinery were assessed using immunoblotting. MQ and MCA induced a loss in mitochondrial function and mtDNA replication machinery as indicated by a reduction in membrane potential, OCR and protein levels. Furthermore, increases in superoxide levels and mtDNA fragmentation were observed with MQ and MCA treatment. Finally, we assessed mitochondrial content using two methods. The first method being the ratio of mitochondrial to nuclear DNA, determined by qPCR of short (∼100bp) nuclear and mitochondrial sequences. The second method was the ratio of mitochondrial outer membrane proteins to cytoplasmic housekeeping proteins, determined by immunoblotting. Both mitochondria DNA and outer membrane proteins decreased with MQ and MCA treatment suggesting that redox-active mitochondrial-targeted agents may reduce the mitochondrial content in cancer cells. Citation Format: Kaytee L. Pokrzywinski, Thomas G. Biel, Dmitry Kryndushkin, V. Ashutosh Rao. The impact of mitochondrially targeted oncology agents on mitochondrial DNA (mtDNA) integrity. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3005.
Satb2 Is Required for the Development of a Spinal Exteroceptive Microcircuit that Modulates Limb Position
Authors: Kathryn L. Hilde, Ariel J. Levine, Christopher A. Hinckley, Marito Hayashi, Jessica M. Montgomery, Miriam Gullo, Shawn P. Driscoll, Rudolf Grosschedl, Yoshinori Kohwi, Terumi Kohwi-Shigematsu, Samuel L. Pfaff
Journal: Neuron (2016)